secwatch.observer — SEC 8-K summary
======================================

Issuer:     OmniAb, Inc. (OABI)
CIK:        0001846253
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001846253-23-000064
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OmniAb Q1 2023 revenue $16.9M, net loss $6.1M; 301 active partner programs
--------------------------------------------------------------------------

- Revenue $16.9M, up from $9.6M YoY, driven by $10.0M milestone from TECVAYLI EU commercial sale.
- Net loss $6.1M ($0.06/share) vs $6.3M ($0.08/share) YoY; cash & investments $113.6M.
- 301 active programs, 27 in clinical/commercial; new license with Neurocrine Biosciences post-quarter.
- Introduced OmniDeep in silico platform; Seagen's SGN-BB228 entered Phase 1 for melanoma.
- Immunovant expects Phase 2 Graves' disease results H2 2023; CStone sBLA for sugemalimab in ESCC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1846253/000184625323000064/0001846253-23-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1846253/000184625323000064/lgnd-20230511.htm
  HTML page:      https://secwatch.observer/filing/0001846253-23-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer